EDP Sciences and the American Society of ExtraCorporeal Technology (AmSECT) are delighted to announce a new publishing partnership. From 1 January 2023, the Journal of ExtraCorporeal Technology(JECT), AmSECT’s flagship publication, will be published by EDP Sciences. The partners are also pleased to announce that from the same time, JECT will become a fully gold open access journal ensuring the highest possible accessibility to quality research in the field of Perfusion. To support this move to open access, AmSECT will fully fund the cost of article processing charges (APCs) for AmSECT members. Another benefit of the partnership is an agreement to digitize the JECTarchives which date back to 1967 and contain a wealth of valuable content.

JECT is the longest, continuously published periodical in the field of Perfusion and has hitherto been self-published by AmSECT based in Chicago, IL, USA. It has served as the official publication of AmSECT since 1967 and supports a global community of perfusionists, anesthesiologists, surgeons, and researchers in these fields where technology evolves continually. Its international editorial board is comprised of leading experts from several countries.

Speaking on the new agreement, Agnès Henri, Managing Director, EDP Sciences, said, “we are honored to be chosen by AmSECT as the publisher for JECT. We are excited to work with the society and editorial team to build on the influence and impact built over many years, and see a very strong and sustainable future for it as it moves to be fully open access.”

Kim Wiatr, Executive Director, AmSECT, said, “although JECT has been proudly self-published for more than 55 years, we realize that there are limitations to self-publication, especially in terms of visibility and impact. It was therefore important for us to find the right partner to support us in taking the journal to the next level of quality and professionalism and therefore increasing the journal’s value to members and its stature in scholarly communication.” Tami Rosenthal, President of AmSECT continued, “We are delighted that JECT has found a new home with EDP Sciences, an open access specialist. We look forward to the next exciting phase of the journal’s development, including digitization of the archives which could not have been possible before now.”

Dr. Raymond Wong, Editor in Chief of JECT said, “I look forward to working with EDP Sciences to strengthen and grow our international reputation. We are delighted to transition JECT to be fully open access, this move will ensure greater visibility and impact for the high-quality research that we publish, strengthening the journal’s contribution to perfusion research for the benefit of all.”

EDP Sciences is an established open access, society publisher and offers a comprehensive suite of flexible services to learned societies with publishing programs. Existing partners are located throughout the world and serve a range of disciplines.

PREreview and eLife are pleased to announce today that the Chan Zuckerberg Initiative (CZI) has awarded a grant to the non-profit organisations. The investment will boost their efforts to enable more diverse communities of researchers to participate in the open peer review of preprints.

PREreview and eLife have been partners for more than a year. Their collaboration involves improving technology and research culture to support a more open and participatory ecosystem for the public review of preprints. They are currently working to enhance PREreview’s integration into Sciety – a website developed by a team within eLife for users to explore and curate evaluated preprints – and opening up new opportunities for more researchers to participate in public preprint review.

With backing from CZI, the organisations are in a strong position to achieve two key goals over the next two years. The first is to develop PREreview’s software and engagement strategies to allow new communities to solicit and create expert feedback on preprints. The second is to help enable reviewing organisations and societies to implement their own flavours of the ‘publish, review, curate’ model that PREreview and Sciety are showcasing, by building systems that facilitate and display expert reviews and curated lists.

Daniela Saderi, Co-Founder and Director of PREreview, says: “We are grateful to CZI for their support which will help us strengthen our important and innovative work to build a space and opportunities for all researchers to contribute to preprint reviews in ways that feel safe and rewarding to them. We’re excited to continue our work with eLife and Sciety so that together we can help build a robust system that fulfils the needs of preprint authors, reviewers and readers around the world.”

Since eLife’s inception, accelerating discovery and increasing equity in science and medicine have been at the heart of its mission. The organisation shares a common goal with PREreview to provide a space where researchers from all backgrounds can provide open and constructive reviews of new findings posted as preprints. Similarly, across its focus areas of Science, Education, and Community, CZI pairs building technology with grant-making, impact investing and collaboration to help accelerate the pace of progress towards an equitable future.

Damian Pattinson, eLife Executive Director, says: “The Chan Zuckerberg Initiative is well aligned with eLife and PREreview in its goals for the future of science and we’re delighted that they’ve chosen to award us a grant to continue our work. The investment provides a runway to grow both platforms – PREreview and Sciety – and continue offering open review and curation to more communities.”

Dario Taraborelli, Science Program Officer at CZI, says: “We’re thrilled to partner with PREreview and eLife in their efforts to engage the broader scientific community in open peer review of preprints, particularly for early-career researchers and those in underrepresented geographical regions.”

To read more about CZI’s Open Science program, visit http://czi.co/OpenScience.

For more information about eLife and PREreview’s partnership to date, see https://elifesciences.org/for-the-press/a5f813bc/elife-and-prereview-extend-partnership-to-boost-community-engagement-in-open-peer-review.

Figshare integration is rolled out across further titles in the Nature portfolio, extending Springer Nature’s commitment to open science 

In a further move to support open research, more journals in the Nature Portfolio – including Nature itself – will now provide authors with the opportunity to openly share their data, thanks to an integration with Figshare.

The wider rollout follows a successful pilot between Springer Nature and Figshare and is driven by author uptake.

Availability of data is key in supporting the reproducibility of research and driving forward open science, yet researchers tell us that despite the positive impacts, less than 40% of authors actively make their data available. In April of this year, Springer Nature and Figshare announced a new integrated route for data deposition at Nature Portfolio titles to help address this problem and encourage researchers to share data rather than seeing it as a hurdle to article publication. 

Following the success of the pilot, this streamlined integration is now being extended. Authors submitting to the Nature Portfolio journals, including Nature, in the fields of life, health, chemical and physical sciences will now be able to easily opt into data sharing, via Figshare, as part of one integrated submission process.

Graham Smith, Open Data Programme Manager, Springer Nature, said of the integration:

“Through the early pilot we have been able to test appetite for a more streamlined, integrated way to share data, where the admin-heavy tasks associated with data sharing, such as finding a suitable repository and registering and linking data, are removed. Author uptake was incredibly popular, with 1 in 6 authors during this time depositing their data in Figshare and using this service. 

“With the extension of this pilot across more Nature Portfolio journals, including Nature, we look forward to collaborating further with Figshare to help develop tools and services to better support authors in open science practice and benefiting from open research.”

The publisher continues to work with each discipline to address the different needs in respect to data sharing – for example working with the Earth Science community to support the Enabling FAIR data commitment, and its preference for data sharing in specialist community repositories, while adding Figshare as an option where these aren’t available.

Mark Hahnel, Figshare Founder and CEO, said:

“We know researchers need help in making their data available. As the funder mandates get stronger, the ask on these researchers is growing. While it is hugely important for the future of research, we do need ways to make it easier to comply – so it’s fantastic to see Springer Nature continue to work hard for their authors. It is wonderful that this policy involves some of the most impactful journals, where some of the most significant research is being communicated.”

Springer Nature is committed to promoting, collaborating on and advancing solutions to support sustainable open research practices. This extended partnership and integration with Figshare is one example. More on Springer Nature’s drive around open research practices can be found here and here. More on the partnership can be found here.

Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today revealed its 2022 list of Highly Cited Researchers™ – individuals at universities, research institutes and commercial organizations who have demonstrated a disproportionate level of significant and broad influence in their field or fields of research. The methodology draws on data from the Web of Science™ citation index, together with analysis performed by bibliometric experts and data scientists at the Institute for Scientific Information (ISI)™ at Clarivate.  

ISI analysts have awarded Highly Cited Researcher 2022 designations to 6,938 researchers from across the globe who demonstrated significant influence in their chosen field or fields over the last decade. The list is truly global, spanning 69 countries or regions and spread across a diverse range of research fields in the sciences and social sciences. 

This year Clarivate extended the qualitative analysis of the Highly Cited Researchers list, to address increasing concerns over potential misconduct (such as plagiarism, image manipulation, fake peer review). With the assistance of Retraction Watch and its unparalleled database of retractions, Clarivate analysts searched for evidence of misconduct in all publications of those on the preliminary list of Highly Cited Researchers. Researchers found to have committed scientific misconduct in formal proceedings conducted by a researcher’s institution, a government agency, a funder or a publisher are excluded from the list of Highly Cited Researchers. 

David Pendlebury, Head of Research Analysis at the Institute for Scientific Information at Clarivate said: “Research misconduct is an ever-increasing concern in our world. Activities such as unusual citation activity and fake peer review may represent efforts to game the system and create self-generated status. This is why we’ve expanded our qualitative analysis this year to ensure the Highly Cited Researchers list reflects genuine, community-wide research influence. Our efforts are part of a wider responsibility across the whole research community to better police itself and uphold research integrity.”  

The key findings for 2022 show: 

6,938 researchers from 69 countries and regions have been named this year. Some extraordinary researchers are recognized in multiple Essential Science Indicators™ (ESI) research fields: 219 named in two fields, 28 named in three fields and 4 named in four fields. Their achievements are truly exceptional and indicate broad, multidisciplinary influence among their peers. Overall, there are 3,981 awards in specific fields and 3,244 awards for cross-field impact, totalling 7,225 awards across all of the individual researchers named this year. 
 

The United States is the institutional home for 2,764 of the Highly Cited Researchers in 2022, which amounts to 38.3% of the total list, down from 43.3% in 2018. While the slow downward loss of share continues for U.S.-based Highly Cited Researchers, the U.S. clearly still leads the world in research influence.  

Mainland China is second this year, with 1,169 Highly Cited Researchers – continuing to close the gap with the U.S. In five years, Mainland China has more than doubled its share of the Highly Cited Researchers population – from 7.9% in 2018 to 16.2% this year. 

The United Kingdom comes in third with 579 researchers or 8.0%. This is a remarkably high number of researchers at the very top of their fields in terms of citation impact, given that the United Kingdom has a population 1/5 the size of the United States and 1/20 the size of Mainland China.  

Germany has pulled ahead of Australia this year – placing Germany at fourth with 369 researchers, and Australia at fifth with 337 researchers. Behind them are Canada (226), the Netherlands (210), France (134), Switzerland (112) and Singapore (106) which is new to the top 10 this year as Spain drops down. 

Harvard University, home to 233 researchers on the list, is once again the institution with the highest concentration of Highly Cited Researchers in the world. Governmental and publicly funded research organizations also feature strongly in the institutional top 10: the Chinese Academy of Sciences comes in second overall (228), narrowing the gap with Harvard, followed by the U.S. National Institutes of Health (113) and Germany’s Max Planck Society (67). TheUniversity of Pennsylvania has joined the top 10 this year, jumping 7 slots from number 17 in 2021. 

Figure 1: Highly Cited Researchers by country/region 

Figure 2: Highly Cited Researchers by research institution or organization 

 
The full Highly Cited Researchers 2022 list and analysis can be found here. 

Follow us on Twitter @ClarivateAG #HighlyCited2022.